Overview

A Safety and Effectiveness Study of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee

Status:
Completed

Trial end date:
2003-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the long-term safety and effectiveness of acetaminophen (4000 mg per day) and naproxen (750 mg per day) in the treatment of osteoarthritis of the hip or knee.

Phase:

Phase 3

Details

Lead Sponsor:

Johnson & Johnson Consumer and Personal Products Worldwide

Collaborator:

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Treatments:

Acetaminophen
Naproxen